|

CEA-targeted CAR-T cells Clinical Trials

5 actively recruiting trials

Pipeline

Phase 1: 4Phase 1/2: 1

Top Sponsors

  • Chongqing Precision Biotech Co., Ltd4
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1

Indications

  • Cancer5
  • Pancreas Cancer4
  • Gastric Cancer4
  • Lung Cancer4
  • Rectal Cancer3

Other5 trials

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Phase 1
CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases
Phase 1
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Phase 1/2
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Phase 1
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.